Letter

Inhaled insulin: Concerns remain

BMJ 2006; 332 doi: 10.1136/bmj.332.7552.1273-e (Published 25 May 2006)
Cite this as: BMJ 2006;332:1273.6

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Niamh M Martin, specialist registrar (n.martin@imperial.ac.uk),
  2. Karim Meeran, consultant
  1. Metabolic Medicine Unit, Hammersmith Hospital, London W12 0HS
  2. Metabolic Medicine Unit, Hammersmith Hospital, London W12 0HS

    EDITOR—Morton-Eggleston and Barrett conclude that the adverse effects of inhaled insulin are not clinically worrisome.1 Insulin is a potent mitogen and growth factor in the lung, leading to concerns that repeated inhaled delivery of insulin results in supraphysiological alveolar insulin deposition which …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular